Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$31.64M
TTM
Current Assets
$89.94M
Q4 2023
Current Liabilities
$3.633M
Q4 2023
Current Ratio
2475.64%
Q4 2023
Total Assets
$94.64M
Q4 2023
Total Liabilities
$4.211M
Q4 2023
Book Value
$90.43M
Q4 2023
Cash
Q4 2023
P/E
-63.44
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020
Revenue $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020
Revenue $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020
Selling, General & Admin $6.824M $3.952M $2.378M $2.055M
YoY Change 72.67% 66.19% 15.72%
% of Gross Profit
Research & Development $24.84M $8.869M $7.419M $3.688M
YoY Change 180.12% 19.54% 101.17%
% of Gross Profit
Depreciation & Amortization $139.0K $64.00K $30.00K $17.00K
YoY Change 117.19% 113.33% 76.47%
% of Gross Profit
Operating Expenses $31.67M $12.82M $9.797M $5.743M
YoY Change 147.0% 30.87% 70.59%
Operating Profit -$31.67M -$12.82M -$9.797M -$5.743M
YoY Change 147.0% 30.87% 70.59%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020
Interest Expense $45.00K $16.00K $131.0K -$9.000K
YoY Change 181.25% -87.79% -1555.56%
% of Operating Profit
Other Income/Expense, Net $45.00K $173.0K $131.0K -$9.000K
YoY Change -73.99% 32.06% -1555.56%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020
Pretax Income -$31.62M -$12.65M -$9.666M -$5.752M
YoY Change 150.02% 30.85% 68.05%
Income Tax $9.000K $0.00 $0.00 $1.000K
% Of Pretax Income
Net Earnings -$31.63M -$12.60M -$9.666M -$5.753M
YoY Change 151.05% 30.35% 68.02%
Net Earnings / Revenue
Basic Earnings Per Share -$1.19 -$0.63 -$1.01 -$0.65
Diluted Earnings Per Share -$1.19 -$0.63 -$401.2K -$238.8K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020
Cash & Short-Term Investments $88.16M $42.09M $17.34M $25.62M
YoY Change 109.45% 142.67% -32.3%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $916.0K $699.0K $64.00K $10.00K
YoY Change 31.04% 992.19% 540.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $89.94M $42.81M $17.43M $25.67M
YoY Change 110.11% 145.58% -32.09%
Property, Plant & Equipment $1.301M $1.347M $94.00K $46.00K
YoY Change -3.41% 1332.98% 104.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.401M $119.0K $823.0K $27.00K
YoY Change 2757.98% -85.54% 2948.15%
Total Long-Term Assets $4.702M $1.466M $917.0K $73.00K
YoY Change 220.74% 59.87% 1156.16%
Total Assets $94.64M $44.27M $18.35M $25.74M
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $3.484M $2.030M $1.413M $941.0K
YoY Change 71.63% 43.67% 50.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $71.00K $26.00K
YoY Change -100.0% 173.08%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.633M $2.104M $1.635M $972.0K
YoY Change 72.67% 28.69% 68.21%
Long-Term Debt $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $578.0K $668.0K
YoY Change -13.47%
Total Long-Term Liabilities $578.0K $668.0K $0.00 $0.00
YoY Change -13.47%
Total Liabilities $4.211M $2.772M $1.635M $972.0K
YoY Change 51.91% 69.54% 68.21%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020
Basic Shares Outstanding 26.59M 19.98M 9.570M 8.790M
Diluted Shares Outstanding 26.59M 19.98M 9.570M 8.790M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.0072 Billion

About BELITE BIO, INC

Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2022-04-29. The firm is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, LBS-008 as an oral daily treatment for STGD1 and Geographic Atrophy patients. In STGD1, it is developing LBS-008 as once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4 which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009 an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

Industry: Pharmaceutical Preparations Peers: Aclaris Therapeutics, Inc. Innoviva, Inc. AERIE PHARMACEUTICALS INC RELMADA THERAPEUTICS, INC. JOHNSON & JOHNSON NGM BIOPHARMACEUTICALS INC PLIANT THERAPEUTICS, INC. REATA PHARMACEUTICALS INC SIGA TECHNOLOGIES INC